Clinical trials: SARS-CoV-2
SARS-CoV-2, Influenza
A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old
The primary goal of this study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1073 compared to co-administered mRNA-1010 and mRNA-1273 vaccines and to the individual vaccines alone in healthy participants.
- Trial name
- NCT05375838
- Testing
- mRNA-1073, mRNA-1010, mRNA-1273
- Where
- 14 sites in United States
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
SARS-CoV-2 Infection, Acute Kidney Injury
Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection
An interventional clinical trial using oral nicotinamide riboside (NR) in hospitalized patients with COVID-19 infection and acute kidney injury to determine the effect of NR on whole blood nicotinamide adenine dinucleotide (NAD+)…
- Trial name
- NIRVANA (NCT04818216)
- Testing
- Nicotinamide riboside
- Where
- 4 sites in United States
- Volunteers
- 28 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
COVID-19, Myocardial Injury
Myocardial Injury and Quality of Life After COVID-19
In this observational study follow-up and dynamic observation will be conducted on the participants recovered from pneumonia caused by COVID-19.
- Conditions
- COVID-19, Myocardial Injury, Myocarditis Post Infection
- Trial name
- NCT04794062
- Where
- Russia
- Volunteers
- 119 people
- Sponsor
- Voronezh Regional Clinical Consultative and Diagnostic Center
SARS-CoV-2, COVID-19
Stopping ACE-inhibitors in COVID-19
ACEI-COVID-19 is a multicenter, randomized trial testing the hypothesis that stopping/replacing chronic treatment with ACE-inhibitors (ACEI) or angiotensin receptor blockers (ARB) improves outcomes in symptomatic…
- Trial name
- ACEI-COVID (NCT04353596)
- Testing
- ACE inhibitor, angiotensin receptor blocker
- Where
- 31 sites in Austria, Germany
- Volunteers
- 216 people
- Sponsor
- Medical University Innsbruck
COVID
Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease
The purpose of this adaptive trial is to determine the clinical efficacy of Ifenprodil in the treatment of patients infected with COVID-19.
- Trial name
- NCT04382924
- Testing
- NP-120 (Ifenprodil)
- Where
- 10 sites in United States, Australia and 2 more
- Volunteers
- 168 people
- Sponsor
- Algernon Pharmaceuticals
COVID, Corona Virus Infection
Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms
The study is a prospective, randomized, controlled investigation designed for comparison of two groups for the reduction of respiratory distress in a CoViD-19 population, using gammaCore Sapphire (nVNS) plus standard of care…
- Conditions
- COVID, Corona Virus Infection, Respiratory Failure, Respiratory Distress Syndrome, Adult
- Trial name
- SAVIORII (NCT04382391)
- Testing
- gammaCore® Sapphire (non-invasive vagus nerve stimulator), Standard of care therapies
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
SARS-CoV-2 Virus Infection
Dose Finding Study to Evaluate The Safety, Tolerability and Immunogenicity of an Inactiviated, Adjuvanted SARS-CoV-2 Virus Vaccine Candidate Against Covid-19 in Healthy Subjects
A multicenter, 3-arm randomized dose finding study in the UK to evaluate safety, tolerability and immunogenicity of a vaccine candidate against Covid-19.
- Trial name
- NCT04671017
- Testing
- VLA2001
- Where
- 4 sites in United Kingdom
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Coronavirus Disease 2019 (COVID-19), Acute Lung Injury
Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure
This was a randomized, double-blind, placebo-controlled Phase 2/3 study to evaluate the safety and efficacy of dociparstat sodium in adult patients with acute lung injury (ALI) due to Coronavirus Disease 2019 (COVID-19).
- Conditions
- Coronavirus Disease 2019 (COVID-19), Acute Lung Injury, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
- Trial name
- NCT04389840
- Testing
- Dociparstat sodium
- Where
- 12 sites in United States
- Volunteers
- 27 people
- Sponsor
- Jazz Pharmaceuticals
COVID-19, Acute Respiratory Distress Syndrome (ARDS)
Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019
This was a Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multicenter, dose escalation and proof-of-concept study to evaluate the safety and efficacy of razuprotafib, administered 3 times daily (TID)…
- Trial name
- RESCUE (NCT04511650)
- Testing
- Razuprotafib Subcutaneous Solution
- Where
- 7 sites in United States
- Volunteers
- 31 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
COVID-19, Coronavirus
Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults
The purpose of this study is to test the safety and efficacy of convalescent donor plasma to treat COVID-19 in hospitalized adults in a randomized, placebo-controlled setting.
- Conditions
- COVID-19, Coronavirus, SARS-CoV-2
- Trial name
- PassItOn (NCT04362176)
- Testing
- pathogen reduced SARS-CoV-2 convalescent plasma
- Where
- 26 sites in United States
- Volunteers
- 974 people
- Sponsor
- Vanderbilt University Medical Center
COVID-19
Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib in the treatment of participants with COVID-19-associated Acute Respiratory Distress Syndrome (ARDS) who require mechanical ventilation.
- Trial name
- NCT04377620
- Testing
- Ruxolitinib
- Where
- 36 sites in United States, Russia
- Volunteers
- 211 people
- Sponsor
- Incyte Corporation
SARS-CoV-2 Infection, COVID-19
A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals
The purpose of this clinical protocol is to learn about the safety, tolerability, and immunogenicity of new BNT162b2 RNA-based vaccine candidates targeting new variants of SARS-CoV-2 in healthy people.
- Trial name
- NCT05997290
- Testing
- BNT162b2 (Omi XBB.1.5), BNT162b2 (Omi JN.1), BNT162b2 (Omi KP.2)
- Where
- 37 sites in United States
- Volunteers
- 1,051 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Sars-CoV-2 Infection, COVID-19
Safe and Healthy Schools
This study will target Madison Metropolitan School District (MMSD) school children ages 4-19 and staff who have not had a previous positive COVID-19 test within the past 3 months.
- Trial name
- NCT05105789
- Testing
- BinaxNOW Test, "Lollipop" swab
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
COVID-19
Povidone-Iodine Oral Rinse Study
This study is a two-arm, randomized, 2-phase study. Phase I will be double blinded clinical trial of the safety and efficacy of an antiseptic mouthwash solution on reducing SARS-CoV-2 load in COVID 19+ adult individuals.
- Trial name
- NCT05239598
- Testing
- Mouth rinse
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Pennsylvania
COVID-19
A Study to Investigate the Pharmacokinetics, Efficacy and Safety of INM005 in Patients With COVID-19.
This study aims to analyze the efficacy and safety of passive immunotherapy by administering an equine hyperimmune serum (INM005) against the SARS-CoV-2 receptor binding domain (RBD) to COVID-19 patients.
- Trial name
- NCT04494984
- Testing
- INM005
- Where
- 19 sites in Argentina
- Volunteers
- 243 people
- Sponsor
- Inmunova S.A.
Influenza, SARS (Severe Acute Respiratory Syndrome)
Predicting Severity and Disease Progression in Influenza-like Illness (Including COVID-19)
Respiratory infections such as colds, flu and pneumonia affect millions of people around the world every year. Most cases are mild, but some people become very unwell.
- Conditions
- Influenza, SARS (Severe Acute Respiratory Syndrome), Respiratory Viral Infection, Respiratory Tract Infections
- Trial name
- PREDICT-ILI (NCT04664075)
- Testing
- Respiratory infections
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- Imperial College London
Covid19, SARS-CoV Infection
SARS-CoV-2 Human Challenge Characterisation Study
This is a dose optimisation study in healthy adults aged 18-30 who will be experimentally inoculated with SARS-CoV-2. The aim is to cause PCR-confirmed upper respiratory infection in the majority of challenged individuals with…
- Conditions
- Covid19, SARS-CoV Infection, Corona Virus Infection, Coronavirus
- Trial name
- NCT04865237
- Testing
- SARS-CoV-2 Virus 1x10^1 TCID50, Remdesivir, SARS-CoV-2 Virus 1x10^2 TCID50
- Where
- 2 sites in United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Long COVID, Long COVID-19
RECOVER-NEURO: Platform Protocol to Measure the Effects of Cognitive Dysfunction Interventions on Long COVID Symptoms
This platform protocol is designed to be flexible so that it is suitable for a wide range of settings within health care systems, for remote settings, and in community settings where it can be integrated into COVID-19 programs…
- Conditions
- Long COVID, Long COVID-19, Long COVID19
- Trial name
- NCT05965752
- Testing
- BrainHQ/Active Comparator Activity, BrainHQ, PASC CoRE
- Where
- 24 sites in United States
- Volunteers
- 328 people
- Sponsor
- Duke University
Coronavirus Disease 2019 (COVID-19)
Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19
The purpose of this study is to assess whether convalescent plasma therapy is associated with reduced 30-day all-cause mortality in a population of Veteran inpatients with non-severe coronavirus disease 2019 (COVID-19).
- Trial name
- NCT04545047
- Testing
- COVID-19 convalescent plasma
- Where
- 2 sites in United States
- Volunteers
- 5,044 people
- Sponsor
- VA Office of Research and Development
SARS-CoV-2 Infection
Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 Infection
A multicenter, randomized, double-blinded, placebo-controlled, phase 3 clinical efficacy study evaluating nitric oxide nasal spray (NONS) as prevention for treatment of individuals at risk of exposure to COVID-19 infection.
- Trial name
- NCT05109611
- Testing
- Nitric Oxide, Nasal spray with isotonic saline
- Where
- 6 sites in Canada, Sri Lanka
- Volunteers
- 1,389 people, healthy volunteers welcome
- Sponsor
- Sanotize Research and Development corp.